Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GJB2 | P29033 | 5/20 | 0.48 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | HPSE | Q9Y251 | 6/20 | 0.34 |
| ▸ | FGF1 | P05230 | 6/20 | 0.34 |
| ▸ | FGF2 | P09038 | 5/20 | 0.34 |
| ▸ | VEGFA | P15692 | 3/20 | 0.34 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.34 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.34 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15883868 | 1.00 | GJB2 (0.48) | GJB2TNFGBA1HPSEFGF1 | |
| SCHEMBL12898703 | 0.94 | GJB2 (0.46) | GJB2TNFGBA1FGF1SLC2A1 | |
| SCHEMBL10291407 | 0.94 | GJB2 (0.50) | GJB2TNFGBA1HPSEFGF1 | |
| SCHEMBL18315050 | 0.94 | GJB2 (0.50) | GJB2TNFGBA1HPSEFGF1 | |
| SCHEMBL10292101 | 0.94 | GJB2 (0.48) | GJB2TNFGBA1HPSEFGF1 | |
| SCHEMBL19204221 | 0.94 | GJB2 (0.48) | GJB2TNFGBA1HPSEFGF1 | |
| SCHEMBL19204198 | 0.91 | GJB2 (0.52) | GJB2TNFGBA1HPSEFGF1 | |
| SCHEMBL19277314 | 0.90 | GJB2 (0.48) | GJB2TNFGBA1HPSEFGF1 | |
| SCHEMBL18311512 | 0.90 | GJB2 (0.49) | GJB2TNFGBA1HPSEFGF1 | |
| SCHEMBL18311516 | 0.88 | GJB2 (0.49) | GJB2TNFGBA1HPSEFGF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120277172-A1 | CARBOHYDRATE-LIPID CONSTRUCTS AND THEIR USE IN PREVENTING OR TREATING VIRAL INFECTION | KODE BIOTECH LIMITED (NZ) | 2012-11-01 | — | — | US | disclosed |
| US-8211860-B2 | Carbohydrate-lipid constructs and their use in preventing or treating viral infection | KODE BIOTECH LIMITED (NZ) | 2012-07-03 | — | — | US | disclosed |
| US-20100184723-A1 | CARBOHYDRATE-LIPID CONSTRUCTS AND THEIR USE IN PREVENTING OR TREATING VIRAL INFECTION | KODE BIOTECH LIMITED (NZ) | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184723-A1 | CARBOHYDRATE-LIPID CONSTRUCTS AND THEIR USE IN PREVENTING OR TREATING VIRAL INFECTION | HAVCR2, SIGLEC7, CD14 | GJB2 4066/4885TNF 1339/4885GBA1 162/4885 |
| US-20120277172-A1 | CARBOHYDRATE-LIPID CONSTRUCTS AND THEIR USE IN PREVENTING OR TREATING VIRAL INFECTION | HAVCR2, SIGLEC7, FUT5 | GJB2 3919/4885TNF 1402/4885GBA1 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.